PURPOSE OF STUDY
THIS STUDY is an analysis of 1,667 cases of scarlet fever observed over a period of fifteen months (April 1944 to June 1945), 466 cases in a civilian hospital for communicable diseases (Willard Parker Hospital, New York) and 1,201 cases in the contagious disease unit of an institution under military control (United States Public Health Service, Sheepshead Bay, N. Y.). The object is to evaluate the effects of gamma globulin as compared with the effects of four other therapeutic agents in scarlet fever—sulfadiazine, human scarlet fever immune serum, scarlet fever streptococcus antitoxin and symptomatic therapy only.Gamma globulin,1 which is the immune globulin fraction of pooled human plasma, is best known at present because of its established worth in the prophylaxis of measles. Other clinical uses for this biologic preparation have been indicated through extensive laboratory investigations and have been the subject of intensive study in
LANDON JF, JACKSON SJ. TREATMENT OF SCARLET FEVER: A Comparison of Gamma Globulin with Other Therapeutic Agents in 1,667 Cases. Am J Dis Child. 1948;76(1):60–72. doi:10.1001/archpedi.1948.02030030067007
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.